ASCO Account:To submit an abstract, you will need to log in with an ASCO.org.org account. If you are not an ASCO member, you can create a guest account. The person submitting the abstract is not required to be an author on the abstract and will be able to select the first/presenting...
ASCO Account:To submit an abstract, you will need to log in with an ASCO.org.org account. If you are not an ASCO member, you can create a guest account. The person submitting the abstract is not required to be an author on the abstract and will be able to select the first/presenting...
本次峰会主题为“破晓之光引领肿瘤诊疗新方向(Shining a Light on Advances in Cancer Care)”。 目前,摘要已公布。在Rapid Oral Abstract Session,乳腺癌领域入选唯一一项研究,报告了2010-2022年I-SPY试验中罕见乳腺癌亚型的治疗效果和结果。...
上海交通大学医学院附属瑞金医院朱正纲教授团队于本次大会将口头报告“腹膜转移性胃癌患者腹膜内和静脉注射紫杉醇加 S-1 与静脉注射紫杉醇加 S-1 的治疗效果对比:来自多中心、随机、Ⅲ期 DRAGON-01 试验的结果”,为胃癌伴腹膜转移患者提供新的治疗希望,摘要详情如下。 研究摘要 Abstract Title:Intraperitoneal and i...
该研究成果是池畔教授牵头开展的“腹腔镜辅助手术治疗低位直肠癌的前瞻性、多中心、随机、开放、平行对照、非劣效临床研究(LASRE研究)”第3次荣登ASCO系列会议,这是继该研究被2022年ACSO年会录用为Poster discussion和2024年ASCO GI录用为Oral Abstract Session(口头报告)之后,再次亮相ASCO年会,是第一项报道低位直肠癌...
2025年美国临床肿瘤学会胃肠道肿瘤研讨会(ASCO GI)上,日本的Susumu Hijioka教授报告了一项依维莫司联合兰瑞肽对比依维莫司单药治疗一线治疗胃肠胰神经内分泌瘤(GEP-NET)的Ⅲ期研究的结果,这是本次大会神经内分泌肿瘤领域唯一的一项口...
[2]Varun Monga,Tanner Michael Johanns,Roger Stupp,et al.A phase 1 study of the protein arginine methyltransferase 5(PRMT5)brain-penetrant inhibitor PRT811 in patients(pts)with recurrent high-grade glioma or uveal melanoma(UM).ASCO 2023;abstract 3008. ...
Whether Telehealth or In Person, Palliative Care Offer Benefits for Patients With Advanced Lung Cancer Joseph Greer, PhD June 7th 2024 Joseph Greer, PhD, discusses the late-breaking abstract from the 2024 ASCO Annual Meeting evaluating telehealth vs in-person palliative care for patients with advance...
5.Lauren Claire Brown, et al. Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: A secondary analysis of the SOFT trial. 2023 ASCO. Abstract #504. J Clin Oncol 41, 2023 (suppl 16; abstr 504). DOI: 10.1...
中山大学肿瘤防治中心马骏教授牵头开展的“PD-1抑制剂信迪利单抗联合诱导化疗和同步放化疗(IC-CCRT)对比IC-CCRT治疗局部区域晚期鼻咽癌(LANPC):一项多中心、Ⅲ期、随机对照临床试验(CONTINUUM)”被列为最新突破性研究(Late-breaking Abstract,LBA),是中国入选的2项LBA口头报告之一。马骏教授受邀在大会上作了精彩报告。